Assessment of complex peptide degradation pathways via structured multicompartmental modeling approaches: The metabolism of dynorphin A1-13 and related fragments in human plasma

Journal of Pharmaceutical Sciences

Volumn 88, Issue 9, 1999, Pages 938-944

  Müller, Stefan ^a,b   Hutson, Alan ^c   Arya, V ^a   Hochhaus, GÜNTHER ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b MUNDIPHARMA GMBH   (Germany)

^c Division of Pulmonary and Critical Care Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYNORPHIN[1-13];

AREA UNDER THE CURVE; ARTICLE; COMPARTMENT MODEL; DRUG DEGRADATION; ENZYME INHIBITION; FIRST PASS EFFECT; MICHAELIS MENTEN KINETICS; PLASMA; PROTEIN METABOLISM;

EID: 0345034782     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js980036d     Document Type: Article

References (14)

1. Mueller, S.; Hochhaus, G. Metabolism of dynorphin A1-13 in human blood and plasma. Pharm. Res. 1995, 12, 1165-1170.
2. Chavkin, C.; Goldstein, A. Specific receptor for the opioid peptide dynorphin: Structure-activity relationship. Proc. Natl. Acad. Sci. U.S.A. 1981, 78, 6643-6547.
3. Takemori, A. E.; Loh, H. H.; Lee, N. N. Suppression by dynorphin A and [des-Tyr1]dynorphin A peptides of the expression of opiate withdrawal and tolerance in morphine-dependent mice. J. Pharm. Exp. Ther. 1993, 266, 121-124.
4. 3H]-L-glutamate in Rat Brain Membranes by Metabolic Dynorphin Fragments. Die Pharmazie 1998,
5. Quillan, J. M.; Sadee, W. Dynorphin Peptides; Antagonists of melanocortin receptors. Pharm. Res. 1997, 14, 713-719.
6. Henriksen, J. H. Kinetics of whole-body and organ degradation. In Degradation of bioactive substances: Physiology and Pathophysiology; Henriksen, J. H., Ed.; CRC: Boca Raton, 1991; pp 3-32.
7. Gibaldi, M.; Perrier, D. Pharmacokinetics; 2nd ed.; Raven: New York, 1982.
8. Micromath, Scientist, Mathematical modeling/differential and nonlinear equations; MicroMath Scientific Software: Salt Lake City, UT, 1993; pp 193-194.
9. Rabitz, H. Systems analysis at the molecular scale. Science 1989, 246, 221-246.
10. Bieniasz, L. K.; Speiser, B. Use of sensitivity analysis methods in the modelling of electrochemical transients. Part 1. Gaining more insight into the behaviour of kinetic models. J. Electroanal. Chem. 1998, 441, 221-246.
11. Bausback, H. H.; Ward, P. E. Degradation of low molecular-weight opioid peptides by vascular plasma membrane aminopeptidase M. Biochim. Biophys. Acta 1986, 882, 437-444.
12. Powell, M. F. Peptide stability in drug development: A comparison of peptide reactivity in different biological media. J. Pharm. Sci. 1992, 81, 731-735.
13. Walker, R.; Krishnaswamy, S. The activation of prothrombin by the prothrombinase complex. The contribution of the substrate-membrane interaction to catalysis. J. Biol. Chem. 1994, 274, 41-50.
14. Otero, M. J.; Iglesias, T.; Fuentes, J. A. Hypoalgesic action of bestatin analogues that inhibit central aminopeptidases, but not neutral endopeptidases. Neuropeptides 1993, 25, 175-182.